Steven Michiels1, Ana Maria Barragán2, Kevin Souris2, Kenneth Poels3, Wouter Crijns3, John A Lee2, Edmond Sterpin4, Sandra Nuyts5, Karin Haustermans5, Tom Depuydt6. 1. Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven - University of Leuven, Belgium. Electronic address: michiels.steven@kuleuven.be. 2. Center of Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Belgium. 3. Department of Radiation Oncology, University Hospitals Leuven, Belgium. 4. Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven - University of Leuven, Belgium; Center of Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Belgium. 5. Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven - University of Leuven, Belgium; Department of Radiation Oncology, University Hospitals Leuven, Belgium. 6. Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven - University of Leuven, Belgium; Department of Radiation Oncology, University Hospitals Leuven, Belgium. Electronic address: tom.depuydt@kuleuven.be.
Abstract
BACKGROUND & PURPOSE: Intensity-modulated proton therapy (IMPT) of superficial lesions requires pre-absorbing range shifter (RS) to deliver the more shallow spots. RS air gap minimization is important to avoid spot size degradation, but remains challenging in complex geometries such as in head-and-neck cancer (HNC). In this study, clinical endpoints were investigated for patient-specific bolus and for conventional RS solutions, making use of a Monte Carlo (MC) dose engine for IMPT optimization. METHODS AND MATERIALS: For 5 oropharyngeal cancer patients, IMPT spot maps were generated using beamlets calculated with MC. The plans were optimized for three different RS configurations: 3D printed on-skin bolus, snout- and nozzle-mounted RS. Organ-at-risk (OAR) doses and late toxicity probabilities were compared between all configuration-specific optimized plans. RESULTS: The use of bolus reduced the mean dose to all OARs compared to snout and nozzle-mounted RS. The contralateral parotid gland and supraglottic larynx received on average 2.9Gy and 4.2Gy less dose compared to the snout RS. Bolus reduced the average probability for xerostomia by 3.0%. For dysphagia, bolus reduced the probability by 2.7%. CONCLUSIONS: Quantification of the dosimetric advantage of patient-specific bolus shows significant reductions compared to conventional RS solutions for xerostomia and dysphagia probability. These results motivate the development of a patient-specific bolus solution in IMPT for HNC.
BACKGROUND & PURPOSE: Intensity-modulated proton therapy (IMPT) of superficial lesions requires pre-absorbing range shifter (RS) to deliver the more shallow spots. RS air gap minimization is important to avoid spot size degradation, but remains challenging in complex geometries such as in head-and-neck cancer (HNC). In this study, clinical endpoints were investigated for patient-specific bolus and for conventional RS solutions, making use of a Monte Carlo (MC) dose engine for IMPT optimization. METHODS AND MATERIALS: For 5 oropharyngeal cancerpatients, IMPT spot maps were generated using beamlets calculated with MC. The plans were optimized for three different RS configurations: 3D printed on-skin bolus, snout- and nozzle-mounted RS. Organ-at-risk (OAR) doses and late toxicity probabilities were compared between all configuration-specific optimized plans. RESULTS: The use of bolus reduced the mean dose to all OARs compared to snout and nozzle-mounted RS. The contralateral parotid gland and supraglottic larynx received on average 2.9Gy and 4.2Gy less dose compared to the snout RS. Bolus reduced the average probability for xerostomia by 3.0%. For dysphagia, bolus reduced the probability by 2.7%. CONCLUSIONS: Quantification of the dosimetric advantage of patient-specific bolus shows significant reductions compared to conventional RS solutions for xerostomia and dysphagia probability. These results motivate the development of a patient-specific bolus solution in IMPT for HNC.
Authors: Alexander R Delaney; Lei Dong; Anthony Mascia; Wei Zou; Yongbin Zhang; Lingshu Yin; Sara Rosas; Jan Hrbacek; Antony J Lomax; Ben J Slotman; Max Dahele; Wilko F A R Verbakel Journal: Cancers (Basel) Date: 2018-11-02 Impact factor: 6.639
Authors: Giovanni Fattori; Ye Zhang; David Meer; Damien Charles Weber; Antony John Lomax; Sairos Safai Journal: Sci Rep Date: 2020-09-18 Impact factor: 4.379
Authors: Minglei Kang; Shaakir Hasan; Robert H Press; Francis Yu; Mashal Abdo; Weijun Xiong; Jehee I Choi; Charles B Simone; Haibo Lin Journal: J Appl Clin Med Phys Date: 2020-12-24 Impact factor: 2.102